Genexine Board Approves KRW 53.87 Billion Collateral for Magok R&D Center Refinancing

• Genexine’s board resolved on Nov. 2, 2026, to provide KRW 53.87 billion in collateral for Magok Consortium First.
• The collateral supports KRW 41.44 billion in borrowing from KB Capital and other financial institutions.
• Collateral represents 21.8% of equity, covering preferential beneficiary rights under a managed land trust and other assets.
• The collateral provision runs from Nov. 6, 2026, through Nov. 5, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genexine Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102900846), on November 02, 2026, and is solely responsible for the information contained therein.